Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.50 p
0.00 p(0.00%)
At close: 4:00 PM EDT
1.50 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume400.24K
Average Volume (3M)2.63M
Market Cap
£5.95M
Enterprise Value12.21M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume4,059,967
30 Day Avg. Volume2,630,265
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Diagnostic PlatformA focused biomarker platform gives the company a clear scientific and commercial objective. If clinical validation and regulatory progress succeed, early-detection diagnostics could support durable demand and strategic partnering interest.
Scalable Licensing ModelA licensing or partnership model could let established healthcare companies handle manufacturing, distribution, and market access. This may reduce the capital required for commercialization and create milestone or royalty opportunities, although contracts are unconfirmed.
Low Reported DebtMinimal reported debt limits interest obligations and reduces direct leverage risk. This provides some financial flexibility compared with a highly indebted development-stage biotechnology company, although weak equity and cash generation remain significant constraints.
Bears Say
Pre-Commercial BusinessThe absence of reported revenue shows that the diagnostic platform has not yet achieved commercial scale. Until validation, regulatory milestones, and customer adoption translate into sales, funding depends heavily on external capital or future partnerships.
Persistent Losses And Cash BurnRecurring operating and free-cash-flow deficits indicate that the business consumes cash while developing its technology. Continued burn can require repeated financing, potentially diluting shareholders and limiting investment in validation and commercialization.
Deteriorating Balance SheetNegative equity and a shrinking asset base materially reduce financial resilience. The company has less capital to absorb development setbacks or fund operations, increasing dependence on successful fundraising, licensing, or other external financing.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £5.95M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 15 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.